The contribution of prothrombotic states to cancer-related stroke
| Autor: | David E. Joyce |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Oncology
medicine.medical_specialty Acute leukemia business.industry Essential thrombocythemia Nonbacterial thrombotic endocarditis medicine.disease Malignancy Thrombosis Cancer procoagulant Polycythemia vera hemic and lymphatic diseases Internal medicine Immunology medicine Cardiology and Cardiovascular Medicine business Stroke |
| Zdroj: | Seminars in Cerebrovascular Diseases and Stroke. 2:151-158 |
| ISSN: | 1528-9931 |
| DOI: | 10.1053/scds.2002.123670 |
| Popis: | Risk factors for cancer-related ischemic stroke are difficult to discern from the traditional risk factors for atheroembolic disorders. Certain hematologic and oncologic malignancies predispose to ischemic stroke. However, contributing pathophysiologic mechanisms are complex, and they cannot often be directly identified as specific causes of a thrombotic event. Generally speaking, interactions between the cellular phase and the plasma phase of coagulation are heightened in malignancy patients. Tissue factor and other procoagulant initiators of thrombosis predominate in certain solid tumor subtypes. Specific malignant hematologic disorders, such as polycythemia vera, essential thrombocythemia, Waldenstrom macroglobulinemia, and subtypes of acute leukemia, are perhaps best characterized as causes of a hypercoagulable state. Solid tumor treatments entail effects of radiation and specific chemotherapy agents that may pose a prothrombotic risk. This review focuses on the pathophysiology of ischemic stroke in malignancy with emphasis on underlying prothrombotic states and the management of these patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect